Open Access<p>miR-596 suppresses the expression of Survivin and enhances the sensitivity of osteosarcoma cells to the molecular targeting agent anlotinib</p>
Author(s) -
Leisheng Wang,
H. S. C. en,
Lei Yang,
Yanbing Zhang,
Baisheng Sun,
Jinliang Gao
Publication year - 2019
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s215145
Subject(s) - survivin , osteosarcoma , cancer research , microrna , medicine , transfection , cell culture , malignancy , oncology , chemistry , biology , cancer , gene , biochemistry , genetics
Osteosarcoma (OSA), the most common primary bone malignancy, is characterized by a wide spectrum of complicated pathologies and frequent distal metastasis and causes death in adolescents and young adults worldwide. Antitumor drug treatment strategies include various cytotoxic chemotherapy drugs, while molecular targeted therapy for OSA is currently less used. The present work revealed the role played by the miR-596/Survivin axis in affecting the sensitivity of OSA cells to anlotinib, a novel molecular targeting agent.